CrushSCI.com
106.6Average days
101Median days
62Fastest days
162Longest days
1,2682025 publications

Paper Review Records

All Paper Review Records

16 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

73 days

Immunization with JN.1 spike protein increases the breadth of binding and neutralizing antibodies in Syrian hamsters in an immune-history dependent manner

Authors
Tamarand L. Darling; Chieh-Yu Liang; Ionsei Hastings; Nadia Soudani; Traci L. Bricker; Mehul Suthar; Ali H. Ellebedy; Michael S. Diamond; Adrianus C.M. BoonShow moreShow less
Affiliations
Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA; Department of Pediatrics, Emory University, Atlanta, GA, USA; Department of Microbiology, Washington University School of Medicine, St. Louis, MO, USAShow moreShow less
Source PDF DOI Publisher page
82 days

Hemagglutinin- and neuraminidase-targeting antibody responses after receipt of egg-based inactivated or recombinant influenza vaccines among adults aged 18–64 years

Authors
Vasiliy P. Mishin; Mira C. Patel; Rongyuan Gao; Lauren Grant; Anton Chesnokov; Philippe Noriel Q. Pascua; Ha T. Nguyen; Chloe Champion; Kurt T. Hegmann; Matthew S. Thiese; Colin Maguire; Sarang K. Yoon; Lori S. Merrill; Rebecca V. Fink; Andrew L. Phillips; Shivaprakash Gangappa; Kristina Wielgosz; Min Z. Levine; Fatimah S. Dawood; Larisa V. GubarevaShow moreShow less
Affiliations
Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA; Rocky Mountain Center for Occupational and Environmental Health, Division of Occupational and Environmental Health, University of Utah Health, Salt Lake City, UT, USA; Westat Inc, Bethesda, MD, USAShow moreShow less
Source PDF DOI Publisher page
85 days

mRNA encoding norovirus VP1 produces antigenically functional virus-like particles in vitro

Authors
Judith M. Reyes Ballista; Courtney David; Amanda Pirrone; Estibaliz Gonzalez-Fernandez; Jiajie Wei; Zhiyun WenShow moreShow less
Affiliations
Infectious Diseases & Vaccines Department, Merck & Co., Inc., West Point, PA, 19486, USA; Discovery Pharmaceutical Sciences Department, Merck & Co., Inc., West Point, PA, 19486, USA; Vaccine Analytical Research and Development Department, Merck & Co., Inc., West Point, PA, 19486, USAShow moreShow less
Source PDF DOI Publisher page
128 days

Hospital-based surveillance of vaccine-preventable diseases in children: a retrospective study in a Dutch tertiary hospital (2024–2025)

Authors
Susanne Heemskerk; Veerle Roels; Jojanneke van Summeren; Louis J. Bont; Joanne G. WildenbeestShow moreShow less
Affiliations
Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands; Netherlands Institute for Health Services Research (Nivel), Utrecht, the NetherlandsShow moreShow less
Source PDF DOI Publisher page
102 days

In silico conservation and HLA-binding profiles of HMPV F and G protein epitopes: implications for universal vaccine development

Authors
Lora Lee Pless; Marissa Pacey Griffith; Kady D. Waggle; Hunter Coyle; Alison Spratt; Alonzo B. Beatty; Monika Johnson; Evan Michael Heffelfinger; Helen Eleni Aslanidou D'Agostino; Michael Susick; Gabriella Alicea; G.K. Balasubramani; Richard K. Zimmerman; Mary Patricia Nowalk; John Williams; Lee H. HarrisonShow moreShow less
Affiliations
Microbial Genomic Epidemiology Laboratory, Center for Genomic Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Family Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Pediatrics, University of Wisconsin – Madison School of Medicine and Public Health, Madison, WI, USAShow moreShow less
Source PDF DOI Publisher page
162 days

Ischemic stroke after bivalent mRNA COVID-19 vaccination and influenza vaccination during the 2022–2023 season: a multi-site self-controlled case series study

Authors
Stanley Xu; Lina S. Sy; Vennis Hong; Paddy Farrington; Sungching C. Glenn; Sunhea Kim; Denison S. Ryan; Julia E. Tubert; Paulina Tong; Bruno J. Lewin; Hung Fu Tseng; Alexandra Carbayo; Cameron Davis; Navdeep S. Sangha; Edward A. Belongia; Maria E. Sundaram; Jennifer C. Nelson; Matthew F. Daley; Nicola P. Klein; Bruce Fireman; Jacob Haapala; Laura P. Hurley; Stephanie A. Irving; Noelle M. Cocoros; Eric S. Weintraub; Jonathan Duffy; Lei QianShow moreShow less
Affiliations
Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA; School of Mathematics and Statistics, The Open University, Milton Keynes, UK; Department of Clinical Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA; Department of Neurology, Los Angeles Medical Center, Kaiser Permanente Southern California, Los Angeles, CA, USA; Marshfield Clinic Research Institute, Marshfield, WI, USA; Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, USA; Institute for Health Research, Kaiser Permanente Colorado, Denver, CO, USA; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA, USA; HealthPartners Institute, Minneapolis, MN, USA; Division of General Internal Medicine, Denver Health, Denver, CO, USA; Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA; Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA, USA; Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA, USAShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Vaccine take to review a manuscript?

As of 2026-11-19, CrushSCI has 16 complete review records for Vaccine. The fastest paper went from submission to acceptance in 62 days (Antibody-mediated functional responses induced by the SchistoShield® schistosomiasis vaccine in disease-naïve and endemic human populations, received 2026-07-01, accepted 2026-09-01); the slowest took 162 days. The average is 106.6 days and the median is 101 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.